Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| COLL | 8-K | mixed | 5/10 | Collegium Pharmaceutical settled its patent litigation with Grünenthal by paying $17 million to terminate the Grünenthal | Oct 19, 2026 |
| TPST | 8-K | neutral | 2/10 | Tempest Therapeutics appointed John W. Frederick to its board of directors, effective October 13, 2026. Mr. Frederick is | Oct 19, 2026 |
| CTY | PRESS-RELEASE | neutral | 5/10 | City Therapeutics closed its upsized IPO of 12,777,777 shares at $18.00 per share, raising approximately $230 million in | Oct 19, 2026 |
| IRON | PRESS-RELEASE | bearish | 7/10 | Disc Medicine announced a $350M underwritten public offering of common stock and pre-funded warrants, with a 30-day unde | Oct 19, 2026 |
| GERN | PRESS-RELEASE | neutral | 2/10 | Geron Corporation granted inducement stock options for 570,000 shares to three new employees at $1.17 per share, a routi | Oct 19, 2026 |
| ABOS | PRESS-RELEASE | neutral | 1/10 | Acumen Pharmaceuticals, Inc. announced it will report its Q3 results on October 26, 2026. | Oct 19, 2026 |
| LLY | SC 13G/A | neutral | 3/10 | Lilly Endowment Inc. filed a Schedule 13G/A disclosing beneficial ownership of 90,066,978 shares of Eli Lilly & Co. comm | Oct 19, 2026 |
| PRPH | SC 13G | neutral | 3/10 | Venkatesan Shyam filed a Schedule 13G disclosing a 5.5% passive stake in ProPhase Labs, Inc. (PRPH), representing 855,10 | Oct 19, 2026 |
| KYTX | SC 13G | neutral | 4/10 | Orin Hirschman, through AIGH Capital Management LLC and related entities, disclosed a passive 5.9% stake in Kyverna Ther | Oct 19, 2026 |
| GSK | 6-K | bullish | 7/10 | GSK announced FDA approval of Jemperli (dostarlimab) as the first and only immunotherapy for adults with MSI-H/dMMR loca | Oct 19, 2026 |
| ADIA | 8-K | neutral | 3/10 | Adia Med, Inc. entered into a Membership Interest Purchase Agreement to sell seven units (7% membership interest) of its | Oct 19, 2026 |
| NRC | 8-K | neutral | 2/10 | NRC Health disclosed that CEO Trent Green was designated as interim principal financial officer on October 14, 2026, wit | Oct 19, 2026 |
| REX | SC 13G/A | neutral | 3/10 | Stuart A. Rose, an insider of REX American Resources Corp, filed a Schedule 13G/A disclosing beneficial ownership of 2,8 | Oct 19, 2026 |
| NRSN | 6-K | neutral | 3/10 | NeuroSense Therapeutics filed a U.S. patent application covering PrimeC (ciprofloxacin + celecoxib) for traumatic brain | Oct 19, 2026 |
| BCDA | 8-K | bullish | 6/10 | BioCardia announced FDA acceptance of its De Novo pre-submission package for the Helix catheter, a transendocardial deli | Oct 19, 2026 |
| BCDA | PRESS-RELEASE | bullish | 6/10 | BioCardia announced FDA acceptance of its De Novo pre-submission package for the Helix transendocardial delivery cathete | Oct 19, 2026 |
| QNRX | ANALYST-UPGRADE | bullish | 4/10 | Canaccord Genuity initiated coverage on QNRX (Quoin Pharmaceuticals Ltd.) with a Buy rating and an $18 price target, imp | Oct 19, 2026 |
| KALA | SC 13G | neutral | 3/10 | Nachum Labkowski filed a Schedule 13G disclosing a 5.0% passive stake in KALA BIO, Inc., representing 966,991 common sha | Oct 19, 2026 |
| MANE | 8-K | bullish | 7/10 | Veradermics announced positive topline Phase 3 data for VDPHL01, an oral extended-release minoxidil, in male pattern hai | Oct 19, 2026 |
| PACB | PRESS-RELEASE | neutral | 4/10 | PacBio announced a multi-year strategic collaboration with Verily Health to integrate its HiFi long-read sequencing with | Oct 19, 2026 |
| RARE | 8-K | neutral | 4/10 | Ultragenyx settled patent litigation with Navinta LLC over DOJOLVI (triheptanoin), granting Navinta a royalty-free licen | Oct 19, 2026 |
| ARGX | 6-K | bullish | 7/10 | argenx announced positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis (IMNM and DM), meeting the pri | Oct 19, 2026 |
| IRLA | 8-K | neutral | 4/10 | IRulya Therapeutics filed an 8-K furnishing an October 2026 corporate presentation. The presentation highlights Phase 2a | Oct 19, 2026 |
| OSTX | 8-K | bullish | 6/10 | OS Therapies completed an initial closing of a warrant exercise inducement and exchange offer, receiving approximately $ | Oct 19, 2026 |
| DWTX | 8-K | mixed | 6/10 | Dogwood Therapeutics announced a $5 million private placement with its largest shareholder, Sealbond Limited (a subsidia | Oct 19, 2026 |
| ONMD | PRESS-RELEASE | neutral | 3/10 | OneMedNet announced its 12th channel partner agreement with a leading global provider of pharmaceutical intelligence and | Oct 19, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a 6-K disclosing weekly B-share repurchase transactions under its ongoing DKK 15 billion buyback prog | Oct 19, 2026 |
| INDV | PRESS-RELEASE | neutral | 1/10 | Indivior Inc. announced it will report its Q3 2026 results. | Oct 19, 2026 |
| SUPN | PRESS-RELEASE | neutral | 1/10 | Supernus Pharmaceuticals, Inc. announced it will report its Q3 2026 results on October 29, 2026. | Oct 19, 2026 |
| DWTX | PRESS-RELEASE | mixed | 5/10 | Dogwood Therapeutics announced a $5M private placement from its largest shareholder, CK Life Sciences, at $1.22/share (4 | Oct 19, 2026 |